Diagnostic tests and personalized therapies are now targeting several key cancer genes: 1. HER2 is found in 15-20 percent of women with breast cancer and also linked to stomach, gynecological, and colorectal cancers. Drugs like trastuzumab and lapatinib block the protein produced by the gene. 2. KRAS genes drive healthy cell division; mutant forms lead to leukemia and lung, colon, or pancreatic cancers. The U.S. would save an estimated $600 million every year if metastatic colorectal cancer patients were tested for it before treatment. Companion diagnostics like the ResponseDX test line can identify mutations and guide doctors' decisions about treatments such as cetuximab and panitumumab.
展开▼
